EDDC Insights

TTC Considerations in Drug Discovery

The “Considerations in Drug Discovery” video series was produced by the Target Translation Consortium (TTC) with the hope of providing critical content in an easily understandable way to aspiring drug discoverers in Singapore and beyond. The less formal, ‘fireside chat’ format aims to present the insights drawn from experts in the field in a more relatable way.

The Importance of Target Validation | TTC Considerations in Drug Discovery Series

Preclinical cancer-target validation: How not to be wrong

Defining the Unmet Need | TTC Considerations in Drug Discovery Series

Cellular assays for Target Validation | TTC Considerations in Drug Discovery Series

In Vitro Biochemical and Biophysical Assays | TTC Considerations in Drug Discovery Series

A Medicinal Chemist’s Perspective | TTC Considerations in Drug Discovery Serie

Discovery and Development of Bio-Therapeutics | TTC Considerations in Drug Discovery SeriesTitle

Considerations in the Development of Cell Therapy | TTC Considerations in Drug Discovery Series

In Vivo Models in Drug Discovery | TTC Considerations in Drug Discovery Series

Navigating the Drug Discovery Journey

EDDC organized a drug discovery and development symposium on 15-16th May 2023 where speakers from EDDC and industry covered a wide range of topics on considerations in small and large molecule drug development. We are providing recordings of some of the talks given for a limited time. Do note that some talks have not been included as we did not have the permissions to record and make them publicly available.

Carol Koh – Target Validation in Early Drug Discovery

Christophe Bodenreider – Hit Discovery & Validation Strategies

Joseph Cherian – A Hit is Not a Lead: A Medicinal Chemist’s Perspective

Klement Foo – Emerging Small Molecule Approaches

Lim Wan Hsin – Targeting RNA with Small Molecules

Wan Kah Fei – Exploring the Realm of Large Molecule Drugs: From Target to Lead Perspective

Snow Lee – New Horizons in Antibody Modalities for Targeted Therapy

Detlev Mennerich – Starting w/ the End in Mind 1: Boehringer Ingelheim’s Approach to External Innov.

Michael Wong – The Importance of Developing a Biomarker & Translational Strategy in Early Drug Discovery

Hannes Hentze – Preclinical In Vivo Studies

Kantharaj Ethirajulu – Preclinical Development

Katherine Wang – Singapore Therapeutics Development Review (STDR)

Drug Discovery: Past, Present and Future

EDDC’s Drug Discovery Symposium 2024 featured a line-up of esteemed speakers who shared their insights on how Drug Discovery has transformed, and will be transforming through past and future years.

Please note that the talk: “A Short Guidance on Success Factors in Drug Development” by Dr Andreas Wallnoefer, was not included as we did not have permission to record and make it publicly available.

Prof Alex Matter – The Challenges for Global Healthcare

Prof William Chin – Evolution of Drug Discovery – Finding Drugs Then and Now

Prof Jackie Hunter – How Bigger Data, Better Questions and AI-driven Tools are Changing Drug Discovery and Development

Navigating the Drug Frontier

EDDC’s Publications in 2024

ESMO 2024 – A Phase 1 Dose Escalation Study Of EBC-129

Your Own Prior Art: How to Avoid Shooting Yourself in the Foot!

Integrated IP Strategy for Platform Technologies and their Products | Mewburn Ellis, 25 Jan 2024

Quick Guide for Projects with Medicinal Chemistry Needs

Preclinical in vivo Studies for Drug Discovery and Development